Obesity Market Gains Weight But Better Drugs Still Needed

The US obesity market is expected to double in size over the next decade with Novo Nordisk’s Saxenda driving the growth – but real progress for the pharmaceutical sector will only come when obesity drugs offer better outcomes than non-pharma methods.

Obesity

The US obesity market is set to grow from $533m to $1.2bn in the next 10 years, according to Datamonitor Healthcare’s obesity forecast. However, there is room for more dramatic growth long term should more efficacious therapeutics come to market. Fewer than than 1% of treatable patients currently receive a pharmacological intervention for obesity. The market could be worth $11.2bn by 2026 if the proportion of obese patients receiving drug therapy increased to 5%, or $22.4bn if it was 10% (see Figure 1).

The predicted boost in the obesity drug market will be mainly contributed by Novo Nordisk AS' liraglutide(Victoza/Saxenda), for which...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category